Pipeline expansion into bladder cancer increases the total addressable market for ivonescimab and signals management's confidence in the platform. Trial enrollment and site activations over the coming quarters will be key catalysts to monitor. The upcoming PDUFA date of November 14, 2026 for ivonescimab in NSCLC (HARMONi study) is a more near-term binary event.
Price Chart
Executive Summary
Summit Therapeutics announced the expansion of its ivonescimab clinical development program into urothelial carcinoma (bladder cancer) with the planned initiation of the global Phase II/III HARMONi-GU1 trial. This marks the first global registrational trial for ivonescimab in a genitourinary cancer, adding to ongoing Phase III studies in NSCLC and CRC, and broadens the drug's potential addressable market.
Key Facts
- HARMONi-GU1 is a global, multi-regional Phase II/III trial evaluating ivonescimab plus enfortumab vedotin (EV) vs pembrolizumab plus EV as first-line therapy in locally advanced or metastatic urothelial carcinoma
- Trial intends to enroll approximately 800 patients through Phase III; Phase II will identify the recommended Phase III dose of ivonescimab in combination with EV
- Phase III primary endpoints are progression-free survival (PFS) and overall survival (OS)
- Global clinical trial site activations planned to begin by Q4 2026
- This is the first global registrational clinical trial of ivonescimab in a genitourinary cancer, adding to the existing 16 Phase III clinical trials across multiple tumor types
- Ivonescimab is not approved by any regulatory authority in Summit's license territories (North America, South America, Europe, Middle East, Africa, Japan); it was approved in China in May 2024
Financial Impact
No financial data or deal terms disclosed in the filing
Risk Factors
- Clinical trial risk: HARMONi-GU1 may fail to meet its primary endpoints of PFS or OS
- Competitive landscape includes established standard-of-care pembrolizumab plus EV and other emerging therapies in 1L urothelial carcinoma
- Execution risk in initiating and enrolling a global multi-regional trial with approximately 800 patients
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001599298-26-000071 |
| Document: a2026_prx0805xannounceme.htm | 0001599298-26-000071 |
| Document: 0001599298-26-000071-index-headers.html | 0001599298-26-000071 |
| Document: 0001599298-26-000071-index.html | 0001599298-26-000071 |
| Document: 0001599298-26-000071.txt | 0001599298-26-000071 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $17.40 $17.85 | ▲ +2.59% | ▲ +1.77% | $16.75 (−3.71%) |
Sep 14, 2026 18d ago | 8-K | $18.42 $16.90 | ▼ −8.25% | ▼ −8.36% | $16.75 (−9.04%) |
Sep 3, 2026 29d ago | 8-K | $17.13 $17.55 | ▲ +2.45% | ▲ +3.60% | $16.75 (−2.19%) |
Aug 26, 2026 5w ago | 8-K | $14.23 $14.60 | ▲ +2.60% | ▲ +2.72% | $16.75 (+17.74%) |
Aug 5, 2026 8w ago | 8-K | $13.53 $15.10 | ▲ +11.60% | ▲ +11.25% | $16.75 (+23.84%) |
Jul 22, 2026 10w ago | 8-K | $14.74 $12.80 | ▼ −13.16% | ▼ −10.76% | $16.75 (+13.67%) |
Jun 12, 2026 16w ago | Insider Cluster | $14.01 $13.75 | ▼ −1.86% | ▼ −2.53% | $16.75 (+19.59%) |
Jun 12, 2026 16w ago | Institutional Cluster | $14.01 $13.75 | ▼ −1.86% | ▼ −2.53% | $16.75 (+19.59%) |
Jun 11, 2026 16w ago | Institutional Cluster | $13.08 $14.07 | ▲ +7.57% | ▲ +7.14% | $16.75 (+28.10%) |
Jun 9, 2026 16w ago | S-3ASR | $13.05 $13.88 | ▼ −6.36% | ▼ −2.93% | $16.75 (−28.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access